ImmuneOnco Biopharmaceuticals (Shanghai) Future Growth
Future criteria checks 0/6
ImmuneOnco Biopharmaceuticals (Shanghai)'s revenue is forecast to decline at 83.2% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 33.5% |
| Revenue growth rate | -83.2% |
| Future return on equity | -845.1% |
| Analyst coverage | Low |
| Last updated | 02 Aug 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1 | N/A | N/A | N/A | 1 |
| 12/31/2025 | 1 | N/A | N/A | N/A | 1 |
| 12/31/2024 | 1 | N/A | N/A | N/A | 1 |
| 12/31/2023 | 8 | -379 | -370 | -368 | N/A |
| 9/30/2023 | 7 | -371 | -328 | -324 | N/A |
| 6/30/2023 | 5 | -362 | -286 | -280 | N/A |
| 3/31/2023 | 6 | -382 | -274 | -259 | N/A |
| 12/31/2022 | 6 | -403 | -262 | -239 | N/A |
| 12/31/2021 | 14 | -733 | -231 | -191 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1541's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if 1541's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 1541's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 1541's revenue is expected to decline over the next 3 years (-83.2% per year).
High Growth Revenue: 1541's revenue is forecast to decline over the next 3 years (-83.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1541 is forecast to be unprofitable in 3 years.